Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine added to RIC allo-HSCT for MDS and AML
NCT01168219Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2010
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jul 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01168219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01168219.